On December 3, 2019 Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, reported that clinical data updates for cirmtuzumab, its investigational anti-ROR1 monoclonal antibody, will be presented at upcoming medical conferences (Press release, Oncternal Therapeutics, DEC 3, 2019, View Source [SID1234551883]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Interim data from the ongoing Phase 1/2 clinical study of cirmtuzumab in combination with ibrutinib in patients with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) will be presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting that will be held December 7-10, 2019, in Orlando, FL.
Abstract: Cirmtuzumab, a ROR1 Targeted mAb, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the CIRLL Phase 1/2 Trial for CLL and MCL (abstract #1755)
Session Name: 642. CLL: Therapy, excluding Transplantation: Poster I
Session Date: Saturday, December 7, 2019
Session Time: 5:30 PM – 7:30 PM
Location: Hall B, Level 2 (Orange County Convention Center)
Initial data from the ongoing, investigator-sponsored Phase 1 clinical study of cirmtuzumab in combination with paclitaxel in patients with Her2 negative, metastatic or locally advanced unresectable breast cancer will be presented at the San Antonio Breast Cancer Symposium (SABCS) that will be held December 10-14, 2019, in San Antonio, TX.
Abstract: Phase 1b Trial of Cirmtuzumab and Paclitaxel for Locally Advanced, Unresectable and Metastatic Breast Cancer
Session Name: PS3. Poster Session 3
Session Date: Thursday, December 12, 2019
Session Time: 5:00 PM – 7:00 PM
Location: Hall 1 (Henry B. Gonzalez Convention Center)
About Cirmtuzumab
Cirmtuzumab is an investigational, potentially first-in-class monoclonal antibody targeting ROR1, or Receptor tyrosine kinase-like Orphan Receptor 1. Cirmtuzumab is currently being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of CLL and MCL, in a collaboration with the University of California San Diego School of Medicine and the California Institute for Regenerative Medicine (CIRM). In addition, an investigator-initiated Phase 1 clinical trial of cirmtuzumab in combination with paclitaxel for women with metastatic breast cancer is being conducted at the UC San Diego School of Medicine. CIRM has also provided funding to support development programs for cirmtuzumab and a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.
ROR1 is a potentially attractive target for cancer therapy because it is an oncofetal antigen – a protein that confers a survival and fitness advantage when reactivated and expressed by tumor cells. When expressed by hematologic malignancies such as CLL and MCL, ROR1 acts as a receptor for the tumor growth factor Wnt5a. Researchers at the UC San Diego School of Medicine discovered that targeting a critical epitope on ROR1 was key to inhibiting Wnt5a activation, specifically targeting ROR1 expressing tumors. This led to the development of cirmtuzumab that binds this critical epitope of ROR1, which is highly expressed on many different cancers but not on normal tissues. Preclinical data showed that when cirmtuzumab bound to ROR1, it blocked Wnt5a signaling, inhibited tumor cell proliferation, migration and survival, and induced differentiation of the tumor cells. Cirmtuzumab is in clinical development and has not been approved by the U.S. Food and Drug Administration for any indication.